Mast Therapeutics (MSTX) : The most positive equity analysts on Mast Therapeutics (MSTX) expects the shares to touch $5, whereas, the least positive believes that the stock will trade at $1 in the short term. The company is covered by 3 Wall Street Brokerage Firms. The average price target for shares are $2.67 with an expected fluctuation of $2.08 from the mean.
Mast Therapeutics (MSTX) : The consensus on Mast Therapeutics (MSTX) based on 4 analyst recommendation on the company stock is 1, which is interpreted as a Strong Buy recommendation. Zacks Investment Research has issued a rank of 4 which endorses a Sell on the stock. However, 4 brokers have a differing view as they consider the stock to be a Strong Buy at current levels.
Mast Therapeutics (NYSEMKT:MSTX): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $0.44 and $0.44 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $0.60. The buying momentum continued till the end and the stock did not give up its gains. It closed at $0.52, notching a gain of 18.30% for the day. The total traded volume was 18,661,251 . The stock had closed at $0.44 on the previous day.
Mast Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops therapies for serious or life-threatening diseases with unmet needs. The Company leverages its Molecular Adhesion and Sealant Technology (MAST) platform, to develop MST-188 (vepoloxamer) Injection, the Companys lead product candidate. Vepoloxamer is being tested in a Phase III clinical study called EPIC for the treatment of vaso-occlusive crisis in patients with sickle cell disease. The Company also develops AIR001, a sodium nitrite solution for intermittent inhalation through nebulizer. AIR001 is being tested in multiple institution-sponsored Phase IIa clinical studies that provide the Company with data on AIR001s potential to treat patients with preserved ejection fraction (HFpEF).